Pulmonary hypertension (PH) is a major cause of morbidity and death in children, and while treatment options for PH in adults are widely researched and established, there is less evidence for pediatric patients. Successful transitions from intravenous (IV) epoprostenol to subcutaneous treprostinil have been documented in adult patients, however information for young patients is lacking. Furthermore, while there have been cases of adults transitioning from SC to IV treprostinil, there have been no reports of children transitioning from IV to SC treprostinil. 

This case report describes a successful transition from IV to SC treprostinil in a pediatric child with WHO Class 3 PH related to interstitial lung disease.